第一类的HSP110抑制剂通过SYK酸化阻断BCR激活在扩散大B细胞淋巴瘤中
Vincent Cabaud Gibouin1,2, Manon Durand1,2, Christophe Boudesco1,2
1INSERM, UMR1231, Université de Bourgogne, 21078, Dijon, France.
Leukemia
|June 21, 2024
概括
热冲击蛋白 HSP110 抑制剂在治疗活性 B 细胞样扩散性大 B 细胞淋巴瘤 (ABC-DLBCL) 方面表现有前途. 这些抑制剂向关键信号通路,在临床前模型中降低癌细胞存活率和瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 激活的B细胞样扩散型大B细胞淋巴瘤 (ABC-DLBCL) 是由失调的B细胞受体 (BCR) 和TLR/MyD88信号驱动的.
- 热冲击蛋白HSP110稳定了MyD88,这表明它在这些途径中发挥了作用,但其参与BCR信号传递的作用尚不清楚.
研究的目的:
- 研究HSP110在ABC-DLBCL中的BCR信号传输中的作用.
- 评估HSP110抑制剂在ABC-DLBCL中的治疗潜力.
主要方法:
- 在ABC-DLBCL细胞系和异种移植模型中利用了第一类HSP110抑制剂.
- 评估了细胞存活率,激酶酸化 (BTK,SYK,AKT) 和蛋白质相互作用.
- 结合的HSP110抑制剂与PI3K抑制剂copanlisib.
主要成果:
- HSP110抑制剂在体外和体内减少了ABC-DLBCL细胞存活率.
- 抑制剂降低了BCR信号酶BTK和SYK的酸化.
- 确定了HSP110与SYK的相互作用,促进SYK酸化.
- 组合疗法在异种移植中协同抑制了瘤生长.
结论:
- 在ABC-DLBCL中,HSP110在BCR/TLR信号通路中起着调节作用.
- HSP110抑制剂显示出作为ABC-DLBCL的新型治疗剂的潜力.
- 结合HSP110和PI3K抑制提供了一个有希望的协同治疗策略.
更多相关视频
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
6.7K
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.2K
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K